The objective response in the combination cohort was 65% compared to 31% in the nivolumab monotherapy group.7 The remarkably similar response rates that were observed in between our study population, the endometrial cancer subgroup and the combination therapy group of CheckMate142 suggests that dMMR/MSI-H may next to anti-PD-1 monotherapy serve as a tumour-agnostic biomarker for dual anti-PD-1/CTLA-4 treatment.16 The gene discussed is CTLA4; the disease is endometrial cancer.